Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Idebenone→

Idebenone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58186-27-9
Molecular formula
C19H30O5
Molecular weight
338.44 g/mol
Drug class
Synthetic benzoquinonemitochondrial electron-transfer agent and antioxidant
Mechanism of action
A short-chain benzoquinone that can transfer electrons directly to complex III of the mitochondrial electron-transport chain, bypassing defective complex I and supporting cellular ATP generation under conditions of complex I dysfunction. It also has antioxidant activity.
Indications / reported uses
  • Treatment of visual impairment in adolescents and adults with Leber’s hereditary optic neuropathy (LHON), within the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/raxone · https://www.medicines.org.uk/emc/product/2269/smpc · https://www.nice.org.uk/guidance/ta1093 · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Synthetic benzoquinone; mitochondrial electron-transfer agent and antioxidant

Mechanism of action

A short-chain benzoquinone that can transfer electrons directly to complex III of the mitochondrial electron-transport chain, bypassing defective complex I and supporting cellular ATP generation under conditions of complex I dysfunction. It also has antioxidant activity.

General use cases

  • Treatment of visual impairment in adolescents and adults with Leber’s hereditary optic neuropathy (LHON), within the authorised product indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Idebenone Environmental Risk Assessment (ERA) (the Idebenone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.